A Phase 1 Trial Explores Psilocybin for Treatment-Resistant OCD

Bottom line: A Phase 1 trial suggests psilocybin-assisted psychotherapy may be explored for treatment-resistant OCD, though results are preliminary and no conclusions can be drawn yet.

A small trial at Canada’s Centre for Addiction and Mental Health (CAMH) is investigating whether psilocybin, the active compound in magic mushrooms, could help individuals with obsessive-compulsive disorder (OCD) who haven’t responded to standard treatments.

What’s being tested

This study looks at the safety, feasibility, and early clinical effects of psilocybin-assisted psychotherapy in people with treatment-resistant OCD. Ten participants received two low-dose psilocybin sessions under supportive conditions, with the aim of seeing if this approach could lead to meaningful reductions in OCD symptoms.

The design at a glance

This Phase 1 trial is the first step in human testing, focusing on safety and early signals of effectiveness. The trial has been completed, but no results have been published or shared publicly. Phase 1 studies are typically small and designed to gather initial data, not to prove a treatment’s success. The research was conducted by CAMH, a major center for mental health research.

Why it matters

For people with OCD who haven’t found relief from traditional treatments, new options are urgently needed. OCD can be a lifelong struggle, with symptoms that severely impact daily life. This trial is one of the first to explore whether psilocybin could be part of a future treatment approach, though it is still very early in the process.

What this does NOT mean yet

This trial is small, and its results are preliminary. Completion of a Phase 1 trial does not mean the treatment is safe, effective, or ready for use. No published findings are available, and many Phase 1 trials do not progress to larger studies. More research would be needed before any conclusions could be drawn about psilocybin’s role in treating OCD.

How to follow it

For the most accurate and up-to-date information, you can review the trial’s record on ClinicalTrials.gov. This page includes details about the study’s design, outcomes, and any published results.

Sources

https://clinicaltrials.gov/study/NCT06299319 | NCT06299319

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.